Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
NCT04385290
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
+49 351 458
- Written informed consent
- Newly diagnosed AML according to the criteria of the World Health Organisation plus the following molecular or cytogenetic specifications:
- Phase I Trial - MODULE:
- t(8;21)/RUNX1-RUNX1T1 or
- inv(16) or t(16;16)/CBFB-MYH11 or
- FLT3-ITD or
- FLT3-tyrosine kinase domain (FLT3-TKD)
- Phase II Trial - MAGNOLIA
- t(8;21)/RUNX1-RUNX1T1 or
- inv(16) or t(16;16)/CBFB-MYH11
- FLT3 wild-type
- Phase II Trial - MAGMA
- FLT3-ITD or
- FLT3-TKD
- Male and female patients with age
- 18 - ≤ 75 years in Phase I Trial - MODULE or Phase II Trial - MAGNOLIA
- 18 - ≤ 60 years in Phase II Trial - MAGMA
- Eastern Cooperative Oncology Group (ECOG) Score of 0-2
- Life expectancy > 14 days
- Adequate hepatic and renal function
- alanine aminotransferase / aspartate transaminase ≤ 2.5 x ULN
- Bilirubin < 2 x upper limits of normal
- Creatinine < 1.5 x upper limits of normal or Creatinine clearance > 40 ml/min
- White blood cell count < 30 × 10^9/L. Note: Hydroxyurea is permitted to meet this criterion.
(all study parts):
- Previous antineoplastic treatment for AML other than hydroxyurea
- Previous treatment with anthracyclines
- central nervous system involvement
- Isolated extramedullary AML
- Uncontrolled infection
- AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g.,
azacytidine or decitabine)
- Any investigational agent within 30 days or 5 half-lives, whichever is greater, prior
to day 1. An investigational agent is defined as an agent with no approved medical use
in adults or in pediatric patients
- Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)
- Strong CYP3A4/5 enzyme inducing drugs unless they can be discontinued or replaced
prior to enrollment
- Any other known disease or concurrent severe and/or uncontrolled medical condition
(e.g., cardiovascular disease including congestive heart failure or active
uncontrolled infection) that could compromise participation in the study
- Impairment of gastrointestinal (GI) function or GI disease that might alter
significantly the absorption of midostaurin
- Confirmed diagnosis of HIV infection or active viral hepatitis
- Cardiovascular abnormalities, including any of the following:
- History of myocardial infarction, angina pectoris, Coronary Artery Bypass
Grafting within 6 months prior to starting study treatment
- Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia),
complete left bundle branch block, high-grade atrioventricular block (e.g.,
bifascicular block, Mobitz type II and third degree atrioventricular block)
- Uncontrolled congestive heart failure
- Left ventricular ejection fraction of < 50%
- Poorly controlled arterial hypertension
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they fulfill at least one of the following criteria:
- Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with
serum follicule stimulating hormone > 40 U/ml)
- Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without
hysterectomy
- Women of childbearing potential must have a negative serum pregnancy test
performed within 7 days before the first dose of study drug
- Continuous and correct application of a contraception method with a Pearl Index
of < 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from
initial study drug administration until at least 7 months after the last dose of
gemtuzumab ozogamicin and at least 4 months after the last dose of midostaurin,
whichever period is longer. A hormonal contraception method must always be
combined with a barrier method (e.g. condom)
- Sexual abstinence
- Vasectomy of the sexual partner
- Sexually active males unless they use a condom during intercourse while taking the
drug during treatment, and for at least 4 months after stopping treatment and should
not father a child in this period. A condom is required to be used also by
vasectomized men as well as during intercourse with a male partner in order to prevent
delivery of the drug via semen
- Unwillingness or inability to comply with the protocol
- Known hypersensitivity to midostaurin, GO, cytarabine or daunorubicin or to any of the
excipients of midostaurin/placebo, GO, cytarabine or daunorubicin.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- München, Bayern
- Essen, NRW
- Dresden,
- Frankfurt am Main,
- Heidelberg,
- Jena,
- Kiel,
- Leipzig,
- Mannheim,
- Münster,
- Nürnberg,
- Ann Arbor, Michigan
- Omaha, Nebraska
- Chicago, Illinois
- Indianapolis, Indiana
- Hershey, Pennsylvania
Descriptive Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
Brief Title ICMJE | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | ||||||||
Official Title ICMJE | MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | ||||||||
Brief Summary | This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation. | ||||||||
Detailed Description | Acute myeloid leukemia is a malignancy that is still fatal for the majority of patients. Besides age, the genetic configuration of AML blasts is one of the strongest prognostic factors. Patients with mutations in the core-binding factor (CBF) genes have the best prognosis, however a considerable proportion of 35-60% will eventually relapse. Mutation and overexpression of receptor tyrosinkinases (RTK) have been proposed as main reasons for relapse development or chemoresistance in CBF AMLs. RTKs like stem cell factor receptor (c-KIT) and FLT3 are of high clinical relevance as they mediate proliferation and differentiation of hematopoietic stem cells. There is evidence that c-Kit mutations and high levels of c-KIT in CBF-AML have adverse effects on survival endpoints indicating c-KIT as potential therapeutic target in this special AML population. Midostaurin can be considered a potent c-KIT inhibitor besides having multi-kinase inhibitory activity for several other kinases of documented or potential pathogenetic relevance for AML, most importantly mutated FLT3. The kinase inhibition ultimately leads to inhibition of proliferation, cell cycle arrest, and apoptosis. Previous studies with other c-KIT inhibitors such as dasatinib showed promising results with respect to survival end points in newly diagnosed CBF AML patients. Midostaurin is considered a more potent c-KIT inhibitor than dasatinib and may be able to potentiate the inhibitory effect on leukemic cell growth. Another important therapeutical target in CBF AML is the sialic acid-binding immunoglobulin-like lectin (CD33) which is expressed on the majority of AML blasts. Gemtuzumab Ozogamicin (GO) is a therapeutic CD33 antibody linked to a strong cytostatic drug (calicheamicin) which causes apoptosis of cancer cells upon internalization. For the combination of GO and standard intensive chemotherapy, metaanalyses of randomized trials have shown that i) a low-dose fractionated administration results in the best tolerability, and ii) among AML subgroups, patients with CBF AML have the greatest benefit from GO in addition to standard therapy. Subgroup analyses within the ALFA-0701 (A Randomized Study of Gemtuzumab Ozogamicin With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia Aged of 50-70 Years Old) trial population showing beneficial effects of GO on overall survival, relapse-free survival and event-free survival in patients positive for FLT3 mutation as compared to those negative for FLT3 mutation. Subgroup analyses of the GO registration trial ALFA-0701 showed a significant clinical benefit of the patients displaying a mutation in the FLT3 gene compared to those without this mutation. In Addition, CBF AML patients with FLT3 mutations expressed particularly high levels of CD33 antigen and that CD33 antigen levels were positively correlated to the improved survival after GO treatment. Furthermore, recently published data of two paediatric populations with internal tandem mutation in the FLT3 gene showed reduced relapse rates in GO recipients compared to the control group only receiving standard chemotherapy. These results suggest that GO is a particularly beneficiary agent in FLT3 mutated patients who would currently receive midostaurin in addition to intensive chemotherapy as a standard of care. Hence, from a clinical point of view there is an unambiguous rationale supporting the combination of midostaurin and GO for treatment of AML in the two cytogenetic subgroups: CBF AML and FLT3 mutated AML. GO has become the new treatment standard for patients with CBF AML. The hypothesized positive effect of midostaurin is likely but randomized proof is laking. Midostaurin has become the new treatment standard for AML patients with mutations in the FLT3 gene. The positive effect of GO is shown in a post-hoc subgroup analysis of the ALFA-0701 trial, but prospective randomized proof is lacking. Therefore, the proposed trial intends i) to explore and establish the safe combination of GO plus midostaurin (MODULE) and ii) to evaluate the effect of midostaurin versus placebo added to standard AML chemotherapy plus GO in CBF AML (MAGNOLIA) and iii) to evaluate the effect of GO versus no GO added to standard AML chemotherapy plus midostaurin in FLT3 mutated AML (MAGMA). | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 1 Phase 2 | ||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The phase I dose escalation trial (MODULE) will be conducted according to the 3+3 design. The phase II trial in CBF AML (MAGNOLIA) will be conducted in a double-blinded and randomized manner. The phase II trial in FLT3 mutated AML (MAGMA) will be conducted in a open label and randomized manner. Masking Description: Since the trial part MAGNOLIA is designed to be double-blinded, patients, investigators, site personnel, study team members, and anyone involved in the study conduct will remain blinded to the identity of the study drug midostaurin / placebo from the time of randomization until database lock for the primary endpoint analysis. Primary Purpose: Treatment
| ||||||||
Condition ICMJE | Acute Myeloid Leukemia | ||||||||
Intervention ICMJE |
| ||||||||
Study Arms ICMJE |
| ||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE | 214 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | April 2028 | ||||||||
Estimated Primary Completion Date | May 2021 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria (all study parts):
| ||||||||
Sex/Gender ICMJE |
| ||||||||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
| ||||||||
Listed Location Countries ICMJE | Germany | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04385290 | ||||||||
Other Study ID Numbers ICMJE | TUD-MOSAIC-075 | ||||||||
Has Data Monitoring Committee | No | ||||||||
U.S. FDA-regulated Product |
| ||||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||||
Responsible Party | Technische Universität Dresden | ||||||||
Study Sponsor ICMJE | Technische Universität Dresden | ||||||||
Collaborators ICMJE |
| ||||||||
Investigators ICMJE |
| ||||||||
PRS Account | Technische Universität Dresden | ||||||||
Verification Date | February 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |